

Resume

Xin Chen

Home:

Flat 3C, Building S30
Staff Quarters
University of Macau
Avenida da Universidade
Taipa, Macau SAR
China
Email: xin_ch@hotmail.com
Phone: +853 6558 1387 (Macau)
+86 18165581387 (China)

Work:

Rm 9003a, Building N22
Institute of Chinese Medical Sciences
University of Macau
Taipa, Macau, SAR
China
Email: xchen@um.edu.mo
Phone: +853 8822 4513

Citizenship: the United States of America

Residency: Macau non-permanent resident

Education

Sept. 2013: Doctorate Degree of Medical Sciences (PhD in Immunology). Department of Medicine. Radboud University Nijmegen Medical Centre. Nijmegen, Netherlands (Mentors: Prof. Mihai G Netea, Prof. Leo AB Joosten).

Sept. 1988- June 1991: Doctor of Medicine (Chinese Medicine), Department of Chinese Medicine. Guangzhou University of Chinese Medicine. Guangzhou, Guangdong, China

Sept. 1984- June 1987: Master of Medicine (Chinese Medicine), Department of Chinese Medicine. Hubei University of Chinese Medicine. Wuhan, Hubei, China

Sept. 1979- June 1984: Bachelor of Medicine (Chinese Medicine), Department of Chinese Medicine. Hubei University of Chinese Medicine. Wuhan, Hubei, China

Professional qualifications

- Licensed Doctor of Traditional Chinese Medicine (Health Bureau, Macau SAR, Oct 23, 2019, license No. W/369/2019)
- Licensed Acupuncturist. The Board of Acupuncture, the State of Maryland, USA. (July 2004~present, license No. U01359)
- Diplomate in Acupuncture, National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM), USA. (2003-)
- Qualification for Deputy Chief Physician in Traditional Chinese Medicine. Guangdong Province Technical Cadre Bureau. (Dec 30, 1993. No. 047304)

Professional membership

- Member, The American Association of Immunologists
- Member, Society of Leukocyte Biology
- Vice Chair, Chinese Medicine Immunology Committee, Chinese Society of Immunology
- Member, China Association of Chinese Medicine
- Member, Asia-Pacific Association of Medicine and Bio-Immunology
- Member, International Society of Chinese Medicine

Editorial board

- Deputy Editor (since 1/1/2020), Member (since 2017), Editorial Board, Journal of Leukocyte Biology (IF=5.5)
- Associate Editor, Frontiers in Immunology (IF=7.3)
- Member, editorial board, Chinese Medicine (IF=5.46)
- Member, Cancer Biology and Medicine (IF=5.347)
- Member, editorial board, Rheumatology and Immunology Research
- Member, editorial board, Medical Journal of Kiang Wu

Work experiences and Professional Appointments

2023-

Director, State Key Laboratory of Quality Research in Chinese Medicine (University of Macau), Macau SAR, China

2022-

Director, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China

2021-2023

Interim Director, State Key Laboratory of Quality Research in Chinese Medicine (University of Macau), Macau SAR, China

2020-

Distinguished Professor, Department of Pharmaceutical Sciences, Faculty of Health, University of Macau, Macau SAR, China

Distinguished Professor, Ministry of Education, Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China

2020- 2022

Interim Director and Distinguished Professor, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China

2020-

Joint Director, Guangdong-Hong Kong-Macau joint Laboratory for Chinese Medicine Immunology-related Disease Research

2018- 2020

Deputy Director and Full Professor, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China

2018-

Guest Researcher. Laboratory of Cancer Immunometabolism, Center for Cancer Research. National Cancer Institute (NCI), NIH, Frederick, Maryland, USA

2015-2017

Research Collaborator. Cancer Inflammation Program. Center for Cancer Research. National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.

2014-2018

Full Professor of Biomedical Sciences, Institute of Chinese Medical Sciences, State Key Lab of Quality Research in Chinese Medicine, University of Macau, Macau SAR, China

2011-2014

Senior Scientist, Basic Science Program (BSP), Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI)-Frederick, NIH, Frederick, Maryland, USA

2001-2011

Scientist II, Basic Research Program (BRP), SAIC-Frederick, Inc., National Cancer Institute (NCI)-Frederick, NIH, Frederick, Maryland, USA

1999-2001

Visiting Fellow (Postdoctoral Fellow). Laboratory of Molecular Immunoregulation (LMI), Center for Cancer Research (CCR), National Cancer Institute (NCI)-Frederick, NIH, Frederick, Maryland, USA

1998-1999

Postdoctoral Research Scientist. School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire, UK

1993-1998 (Dec 30, 1983-Sept 30 1998)

Director, Office of Research and Education, Shenzhen Red Cross Hospital (n.k.a. the 2nd People's Hospital of Shenzhen, or the 1st Affiliated Hospital of Shenzhen University), Shenzhen, Guangdong, China

Associate Chief Physician, Department of Traditional Chinese Medicine; Shenzhen Red Cross Hospital

Deputy Director, Shenzhen Clinical Institute of Integrative Medicine. Shenzhen, Guangdong, China

1991-1993 (June 1, 1991- Dec 29, 1993)

Attending physician, Department of Traditional Chinese Medicine, Shenzhen Red Cross Hospital, Shenzhen, Guangdong, China

Research funding

2023-2025: CI. Design and development of new tumor immunomodulators based on scutellarin molecular skeleton. Guangdong Bureau of Science and Technology. CNY 1,000,000 (\$140,000 USD).

2024-2024: PI. CPG2024-00031-ICMS. Role of TNFR2 In the Expansion of Treg Cells Induced by HIV Envelope Glycoprotein gp120. MOP350,000 (\$43,437).

2023-2026: PI. 0007/2022/AKP. Research and development of TNFR2-targeting molecular imaging probes for diagnosis and therapy of cancer. MOP 12,000,000 (\$1.5 million USD)

2023-2023: PI. CPG2023-00025-ICMS. Effect of miR-125b-5p on TNFR2 expression by tumor cells and on the efficacy of cancer immunotherapy. MOP350,000 (\$1.5 million USD)

2023-2024: PI. MYRG2022-00260-ICMS. University of Macau Research Committee Multiple Year Research Grant. The role of TNFR2 signal in the function of CD8 cytotoxic T lymphocytes (CTLs). MOP 608,000.00 (\$75,224.74 USD).

2021-2024: PI. 0099/2021/A2. Macau Science and Technology Development Fund. Small Molecule TNFR2 Inhibitors as Novel Anti-tumor Immunotherapy Drug Candidates. MOP 2,400,000 (\$238,787.00 USD)

2021-2024: PI. Development of anti-human TNFR2 single domain antibody and its application in tumor immunotherapy. Research Institute of Tsinghua, Pearl River Delta. CNY 2,600,000 (\$407,000 USD)

2020-: Co-I. 2020B1212030006. Funds for Guangdong-Hong Kong-Macau joint Laboratory for Chinese Medicine Immunology-related Disease Research. CNY 5,000,000.00 (\$783,000 USD).

2020-2022: PI. MYRG2019-00169-ICMS. University of Macau Research Committee Multiple Year Research Grant. MOP 1,050,000.00 (\$130,260 USD). The role of TNFR2 expressed by tumor cells in tumor growth and metastasis.

2019-2022: PI. 0056/2019/AFJ. National Natural Science Foundation of China (NFSC)- Macau Science and Technology Development Fund. MOP1,878,500 (\$233,356.66). Discovery of TNFR2 antagonists from diversified natural compound library as novel cancer immunotherapeutic agents.

2018-2021: PI. 201/2017/A3. Macau Science and Technology Development Fund. MOP 2,478,000 (\$308,114.52USD). Effect and mechanism of blockade of TNFR2 with antibody and naturally occurring compound(s) derived from Chinese herbs on enhancing anti-tumor immune responses.

2018-2020: PI. MYRG2017-00120-ICMS. University of Macau Research Committee Multiple Year Research Grant. MOP 1,500,000.00 (\$187,032.42 USD). Mechanistic study of the TNFR2 signaling pathways and its regulation of Foxp3 expression in CD4+Foxp3+ regulatory T cells.

2018-2020: Co-PI. MYRG2017-00146-FST. University of Macau Research Committee Multiple Year Research Grant. MOP 1,492,500 (\$186,094.94 USD). Structure, Function, and Natural Compound Inhibitor Identification of Complement C5a Receptors by In silico and In vitro Methods.

2017-2019: PI. MYRG2016-00023-ICMS-QRCM. University of Macau Research Committee Multiple Year Research Grant. MOP 1,450,000 (\$187,030.09 USD). Elimination of regulatory T cell activity by targeting TNFR2 as a novel approach to breast cancer immunotherapy

2015: FTREF (Faculty Teaching and Research Enhancement Fund). MOP 50,000 (\$6234.34 USD)

2015-2018: PI. 014/2015/A1. Macau Science and Technology Development Fund. MOP 3,088,850 (\$385,138.59 USD). A mechanistic study of immune tolerance induced by tetrandrine and other Chinese herb-derived components through regulation of DCs/Tregs and the therapeutic application of such an effect on the treatment of experimental colitis.

2015-2017: PI. 011/2015/A. Macau Science and Technology Development Fund. MOP 443,000 (\$55,236.22 USD). Immunopathogenic effect and mechanism of TNF receptor type 2 in inflammatory bowel disease

2014-2017: PI. SRG2014-00024-ICMS-QRCM. University of Macau Start-up Research Grant. MOP 250,000 (\$31,171.68 USD). Role of TNFR2 in the development of pathogenic effector CD4 T cells in mouse model of colitis.

1999-2014: my research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and [in part] by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E.

1991-1998: PI. Multiple grants from State Administration of Traditional Chinese Medicine (China), Guangdong Administration of Traditional Chinese Medicine and Shenzhen Department of Science and Technology.

Government and Community Service

- Member, Science and Technology Committee, Macau SAR government (2023-)
- Member, Chinese Herbal Medicine Evaluation Expert Committee, Macau SAR government (2022-)
- Member, Chinese medicine evaluation expert advisory committee, Macau SAR government (2022-)
- Member, Medical Affairs Committee, Macau SAR government (2017-)
- Member, Healthcare Occupation Committee, Macau SAR government (2021-)
- Member, Chinese Medical Doctor Qualification Committee, Macau SAR government (2021-)
- Academic advisor, Macau Journal of Chinese Medicine/Macau Society of Chinese Medicine (2018-)

Student life Service (Residential College, University of Macau)

- Fellow, Choi Kai Yau College (2014-)
- Associate, Chao Kuang Piu College (2017-2018)

University Service (University of Macau, UM)

- Member, University Senate (2020-)
- Member, University Research Committee (2020-)
- Member, UM Animal Research Ethics Committee (2015-2020)
- Member, UM Scholarship Committee (2015-2020)
- Member, Graduate Studies Committee (2019-2020)
- Member, UM Vice Rector (Research) Selection committee (2018)
- Member, UM Dean of Graduate School Selection committee (2019)
- Member, UM Academic Staff Promotion Advisory Committee (2019,2021-)

Institute Service (Institute of Chinese Medical Sciences (ICMS), University of Macau)

- Chair, ICMS Laboratory Safety Committee (2015-2020)
- Member, ICMS animal ethics committee (2017-2020)
- Chair, Graduate Studies Committee (2019-2020)

Awards and Honors

- Multiple outstanding research awards issued by Provincial Government of Guangdong and Municipal Government of Shenzhen between 1991~1998.
- Technology Transfer Award (National Cancer Institute, 2005)

Xin Chen, Resume, update: 1/3/2024

- Outstanding Achievement Award (SAIC-Frederick, Inc., 2007)
- National Cancer Institute Director's Intramural Innovation Award (2010)

Patent

1. Joost J. Oppenheim, Dimiter S. Dimitrov, De Yang, **Xin Chen** and Zhongyu Zhu. Human monoclonal antibody targeting tnfr2 for cancer immunotherapy. US Patent granted (No. US11389480B2). July 19, 2022. (licensed to Enosi Life Sciences Corp)
2. **Xin Chen**, Ruixin Li and Shaokui Chen. Scutellarin inhibits TNF-TNFR2 interaction and consequently blocks proliferative expansion of CD4⁺Foxp3⁺ regulatory T cells (Tregs). US patent granted (US11266670B2). March 8, 2022.

Publications

- * **Xin Chen** as corresponding author or co-corresponding author
- **Orcid**: 0000-0002-2628-4027
- Total citation: 6204 (WOS); 7664 (Scopus); 9701 (Google Scholar)
- H-index: 41 (WOS), 46 (Scopus); 47 (Google Scholar)

1. Zhu L, Zhang X, **Chen X**, Yang D, Nie Y, Pan R, Li L, Wang C, Gui H, Chen S, Jing Q, Wang M, Nie Y. Anti-TNFR2 enhanced the antitumor activity of a new HMG1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer. *Biochem Biophys Res Commun*. 2023;653:106-14. Epub 20230216. doi: 10.1016/j.bbrc.2023.02.039. PubMed PMID: 36868074.
2. Yang Y, Wang Q, Zou H, Chou CK, ***Chen X**. Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy. *Pharmaceutics*. 2023;15(4). Epub 20230327. doi: 10.3390/pharmaceutics15041074. PubMed PMID: 37111560; PMCID: PMC10142880.
3. Liao P, Jiang M, Islam MS, Wang Y, ***Chen X**. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. *Front Immunol*. 2023;14:1097090. Epub 20230214. doi: 10.3389/fimmu.2023.1097090. PubMed PMID: 36865537; PMCID: PMC9971721.
4. Li P, Yang Y, Yang X, Wang Y, Chou CK, Jiang M, Zheng J, Chen F, ***Chen X**. TNFR2 deficiency impairs the growth of mouse colon cancer. *Int J Biol Sci*. 2023;19(4):1024-35. Epub 20230122. doi: 10.7150/ijbs.72606. PubMed PMID: 36923938; PMCID: PMC10008691.
5. Islam MS, Wang Z, Abdel-Mohsen M, ***Chen X**, Montaner L. Tissue Injury and Leukocyte Changes in Post-Acute Sequelae of SARS-CoV-2: Review of 2833 Post-acute Patient Outcomes per Immune Dysregulation and Microbial Translocation in Long COVID. *Journal of Leukocyte Biology*. 2023. doi: 10.20944/preprints202210.0342.v1.
6. He T, Chen Y, Yang D, Islam MS, Chou CK, Liu J, Faustman DL, Oppenheim JJ, ***Chen X**. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4(+)Foxp3(+) regulatory T cells. *Cell Oncol (Dordr)*. 2023;46(1):167-77. Epub 20221112. doi: 10.1007/s13402-022-00742-0. PubMed PMID: 36369606.
7. Geng CA, Chen FY, Zheng JB, Liao P, Li TZ, Zhang XM, ***Chen X**, Chen JJ. Rubiginosin B selectively inhibits Treg cell differentiation and enhances anti-tumor immune responses by targeting calcineurin-NFAT signaling pathway. *Phytomedicine*. 2023;116:154898. Epub 20230523. doi: 10.1016/j.phymed.2023.154898. PubMed PMID: 37247590.
8. Engku Abd Rahman ENS, Irekeola AA, Shueb RH, Mat Lazim N, Mohamud R, **Chen X**, Ghazali L, Awang N, Haron A, Chan YY. Aberrant frequency of TNFR2-expressing CD4+ FoxP3+ regulatory T cells in nasopharyngeal carcinoma patients. *Cytokine*. 2023;170:156341. Epub 20230830. doi: 10.1016/j.cyto.2023.156341. PubMed PMID: 37657236.
9. Chen Y, Jiang M, ***Chen X**. Therapeutic potential of TNFR2 agonists: a mechanistic perspective. *Front Immunol*. 2023;14:1209188. Epub 20230817. doi: 10.3389/fimmu.2023.1209188. PubMed PMID: 37662935; PMCID: PMC10469862.

10. ***Chen X**, Plebanski M. Editorial: The role of TNF-TNFR2 signal in immunosuppressive cells and its therapeutic implications, volume II. *Front Immunol.* 2023;14:1227003. Epub 20230801. doi: 10.3389/fimmu.2023.1227003. PubMed PMID: 37600778; PMCID: PMC10432281.
11. Xi L, Lin Z, Qiu F, Chen S, Li P, **Chen X**, Wang Z, Zheng Y. Enhanced uptake and anti-maturation effect of celastrol-loaded mannoseylated liposomes on dendritic cells for psoriasis treatment. *Acta Pharmaceutica Sinica B.* 2022;12(1):339-52. doi: <https://doi.org/10.1016/j.apsb.2021.07.019>.
12. Lambuk L, Ahmad S, Sadikan MZ, Nordin NA, Kadir R, Nasir NAA, **Chen X**, Boer J, Plebanski M, Mohamud R. Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma. *Front Immunol.* 2022;13:857812. Epub 2022/06/03. doi: 10.3389/fimmu.2022.857812. PubMed PMID: 35651608; PMCID: PMC9149562.
13. Jiang M, Yang Y, Niu L, Li P, Chen Y, Liao P, Wang Y, Zheng J, Chen F, He H, Li H, ***Chen X**. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. *Journal for ImmunoTherapy of Cancer.* 2022;10(11):e005241. doi: 10.1136/jitc-2022-005241.
14. He T, Chen Y, Yang D, Islam MS, Chou C-K, Liu J, Faustman DL, Oppenheim JJ, ***Chen X**. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells. *Cellular Oncology.* 2022. doi: 10.1007/s13402-022-00742-0.
15. Cheng P, Huang N, Jiang ZY, Zhang Q, Zheng YT, Chen JJ, Zhang XM, Ma YB. 1-Aryltetrahydroisoquinoline analogs as active anti-HIV agents in vitro. *Bioorg Med Chem Lett.* 2022;18(7):2475-8. Epub 20080219. doi: 10.1016/j.bmcl.2008.02.040. PubMed PMID: 18316190.
16. Chen Z, Zhang Y, Wang M, Islam MS, Liao P, Hu Y, ***Chen X**. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. *Int J Biol Sci.* 2022;18(12):4629-41. Epub 2022/07/26. doi: 10.7150/ijbs.73583. PubMed PMID: 35874952; PMCID: PMC9305266.
17. Chen S, Lin Z, He T, Islam MS, Xi L, Liao P, Yang Y, Zheng Y, ***Chen X**. Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4(+)Foxp3(+) Regulatory T Cells and Alleviates Imiquimod-Induced Psoriasis in Mice. *Front Immunol.* 2022;13:800283. Epub 2022/04/26. doi: 10.3389/fimmu.2022.800283. PubMed PMID: 35464441; PMCID: PMC9020220.
18. Chen S, Liao P, Xi L, Yang Y, Wu W, Islam MS, Lin Z, Zheng Y, ***Chen X**. The Therapeutic Effect of Tacrolimus in a Mouse Psoriatic Model is Associated with the Induction of Myeloid-derived Suppressor Cells. *Rheumatol Immunol Res.* 2022;3(4):190-7. Epub 20221231. doi: 10.2478/rir-2022-0034. PubMed PMID: 36879838; PMCID: PMC9984933.
19. Chen S, Li R, Chen Y, Chou C-K, Zhang Z, Yang Y, Liao P, Wang Q, ***Chen X**. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4+Foxp3+ regulatory T cells. *Biomedicine & Pharmacotherapy.* 2022;151:113187. doi: <https://doi.org/10.1016/j.biopha.2022.113187>.
20. Chen F-Y, Geng C-A, Chou C-K, Zheng J-B, Yang Y, Wang Y-F, Li T-Z, Li P, Chen J-J, ***Chen X**. Distepharinamide, a novel dimeric proaporphine alkaloid from *Diploclisia glaucescens*, inhibits the differentiation and proliferative expansion of CD4+Foxp3+ regulatory T cells. *Phytomedicine.* 2022;107:154482. doi: <https://doi.org/10.1016/j.phymed.2022.154482>.
21. bin Z, Yang Y, ***Chen X**. TNFR2 对 CD4+Foxp3+Treg 的活化、增殖及功能影响的研究进展. *现代免疫学.* 2022;42.

22. Yang Y, Islam MS, Hu Y, *Chen X. TNFR2: Role in Cancer Immunology and Immunotherapy. *Immunotargets Ther.* 2021;10:103-22. Epub 2021/04/29. doi: 10.2147/itt.S255224. PubMed PMID: 33907692; PMCID: PMC8071081.
23. Wang Y, Zheng J, Islam MS, Yang Y, Hu Y, *Chen X. The role of CD4⁺FoxP3⁺ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. *Int J Biol Sci.* 2021;17(6):1507-20. Epub 2021/04/29. doi: 10.7150/ijbs.59534. PubMed PMID: 33907514; PMCID: PMC8071774.
24. Liu K, Gu Z, Islam MS, Scherngell T, Kong X, Zhao J, Chen X, Hu Y. Global landscape of patents related to human coronaviruses. *Int J Biol Sci.* 2021;17(6):1588-99. Epub 2021/04/29. doi: 10.7150/ijbs.58807. PubMed PMID: 33907523; PMCID: PMC8071764.
25. Lin Z, Xi L, Chen S, Tao J, Wang Y, Chen X, Li P, Wang Z, Zheng Y. Uptake and trafficking of different sized PLGA nanoparticles by dendritic cells in imiquimod-induced psoriasis-like mice model. *Acta Pharm Sin B.* 2021;11(4):1047-55. Epub 2021/05/18. doi: 10.1016/j.apsb.2020.11.008. PubMed PMID: 33996416; PMCID: PMC8105876.
26. Li P, Chen F, Zheng J, Yang Y, Li Y, Wang Y, *Chen X. Cyclophosphamide abrogates the expansion of CD4⁺Foxp3⁺ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas. *Cancer Biol Med.* 2021. Epub 2021/08/12. doi: 10.20892/j.issn.2095-3941.2021.0027. PubMed PMID: 34378880.
27. Jiang M, Liu J, Yang D, Tross D, Li P, Chen F, Alam MM, Faustman DL, Oppenheim JJ, *Chen X. A TNFR2 antibody by countering immunosuppression cooperates with HMG1 and R848 immune stimulants to inhibit murine colon cancer. *International Immunopharmacology.* 2021;101:108345. doi: <https://doi.org/10.1016/j.intimp.2021.108345>.
28. Islam MS, Yang Y, *Chen X. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4⁺Foxp3⁺Regulatory T Cells: Implications in the Treatment of Autoimmune Diseases and Cancer. *Adv Exp Med Biol.* 2021;1278:257-72. Epub 2021/02/02. doi: 10.1007/978-981-15-6407-9_13. PubMed PMID: 33523452.
29. Chen S, Lin Z, Xi L, Zheng Y, Zhou Q, *Chen X. Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis. *J Leukoc Biol.* 2021;110(6):1047-55. Epub 2021/09/09. doi: 10.1002/jlb.2ma0121-082r. PubMed PMID: 34494306.
30. Ye LL, Peng WB, Niu YR, Xiang X, Wei XS, Wang ZH, Wang X, Zhang SY, Chen X, Zhou Q. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. *Ann Transl Med.* 2020;8(24):1647. Epub 2021/01/26. doi: 10.21037/atm-20-7181. PubMed PMID: 33490159; PMCID: PMC7812164.
31. Yang Y, Islam MS, Wang J, Li Y, *Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. *Int J Biol Sci.* 2020;16(10):1708-17. Epub 2020/04/01. doi: 10.7150/ijbs.45538. PubMed PMID: 32226288; PMCID: PMC7098036.
32. Wang J, Jiang M, *Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *J Leukoc Biol.* 2020;108(1):17-41. Epub 2020/06/14. doi: 10.1002/jlb.3covr0520-272r. PubMed PMID: 32534467; PMCID: PMC7323250.

33. Li P, Yang X, Yang Y, He H, Chou CK, Chen F, Pan H, Liu L, Cai L, Ma Y, ***Chen X**. Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. *J Control Release*. 2020;319:87-103. Epub 2019/12/22. doi: 10.1016/j.jconrel.2019.12.025. PubMed PMID: 31862360.
34. He T, Yang D, Li XQ, Jiang M, Islam MS, Chen S, Chen Y, Yang Y, Chou CK, Trivett AL, Oppenheim JJ, ***Chen X**. Inhibition of two-pore channels in antigen-presenting cells promotes the expansion of TNFR2-expressing CD4⁺Foxp3⁺ regulatory T cells. *Sci Adv*. 2020;6(40). Epub 2020/10/02. doi: 10.1126/sciadv.aba6584. PubMed PMID: 32998896; PMCID: PMC7527222.
35. Chou CK, ***Chen X**. Preferential Expansion of CD4⁺Foxp3⁺ Regulatory T Cells (Tregs) In Vitro by Tumor Necrosis Factor. *Methods Mol Biol*. 2020;2111:71-8. Epub 2020/01/15. doi: 10.1007/978-1-0716-0266-9_6. PubMed PMID: 31933199.
36. Azid NA, Ahmad S, Boer JC, Al-Hatamleh MAI, Mohammad N, Mohd Ashari NS, Tan HT, **Chen X**, Plebanski M, Mohamud R. A profile of TNFR2⁺ regulatory T cells and CD103⁺ dendritic cells in the peripheral blood of patients with asthma. *Hum Immunol*. 2020;81(10-11):634-43. Epub 2020/08/11. doi: 10.1016/j.humimm.2020.07.006. PubMed PMID: 32771274.
37. Zou H, He T, ***Chen X**. Tetrandrine inhibits differentiation of proinflammatory subsets of T helper cells but spares de novo differentiation of iTreg cells. *Int Immunopharmacol*. 2019;69:307-12. Epub 2019/02/16. doi: 10.1016/j.intimp.2019.01.040. PubMed PMID: 30769211.
38. Zhu L, Li P, Gao D, Liu J, Liu Y, Sun C, Xu M, **Chen X**, Sheng Z, Wang R, Yuan Z, Cai L, Ma Y, Zhao Q. pH-sensitive loaded retinal/indocyanine green micelles as an "all-in-one" theranostic agent for multi-modal imaging in vivo guided cellular senescence-photothermal synergistic therapy. *Chem Commun (Camb)*. 2019;55(44):6209-12. Epub 2019/05/11. doi: 10.1039/c9cc02567g. PubMed PMID: 31073580.
39. Yang Yang, **Chen X**. The research progress of inhibition of tumor-associated regulatory T cells by traditional Chinese medicine and its active ingredients. *Chinese Journal of Nature*. 2019;41(4):261-5. doi: 10.3969/j.issn.0253-9608.2019.04.004.
40. He J, Li R, Chen Y, Hu Y, ***Chen X**. TNFR2-expressing CD4⁺Foxp3⁺ regulatory T cells in cancer immunology and immunotherapy. *Prog Mol Biol Transl Sci*. 2019;164:101-17. Epub 2019/08/07. doi: 10.1016/bs.pmbts.2019.03.010. PubMed PMID: 31383403.
41. Chen Y, ***Chen X**. Ancient herbal component may be a novel therapeutic for gouty arthritis. *J Leukoc Biol*. 2019;105(1):7-9. Epub 2018/12/06. doi: 10.1002/jlb.3ce1018-384r. PubMed PMID: 30517770.
42. Al-Hatamleh MAI, E ARE, Boer JC, Ferji K, Six JL, **Chen X**, Elkord E, Plebanski M, Mohamud R. Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor-An Opportunity for Cancer Treatment. *Cells*. 2019;9(1). Epub 2019/12/28. doi: 10.3390/cells9010033. PubMed PMID: 31877663; PMCID: PMC7016661.
43. Al-Hatamleh MAI, Ahmad S, Boer JC, Lim J, **Chen X**, Plebanski M, Mohamud R. A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy. *J Oncol*. 2019;2019:6313242. Epub 2019/06/27. doi: 10.1155/2019/6313242. PubMed PMID: 31239840; PMCID: PMC6556275.

44. ***Chen X**, Plebanski M. Editorial: The Role of TNF-TNFR2 Signal in Immunosuppressive Cells and Its Therapeutic Implications. *Front Immunol.* 2019;10:2126. Epub 2019/09/27. doi: 10.3389/fimmu.2019.02126. PubMed PMID: 31555303; PMCID: PMC6742683.
45. Zou H, Li R, Hu H, Hu Y, ***Chen X**. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. *Front Immunol.* 2018;9:594. Epub 2018/04/11. doi: 10.3389/fimmu.2018.00594. PubMed PMID: 29632537; PMCID: PMC5879105.
46. Shaikh F, He J, Bhadra P, ***Chen X**, Siu SWI. TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders. *Front Immunol.* 2018;9:1382. Epub 2018/07/04. doi: 10.3389/fimmu.2018.01382. PubMed PMID: 29967617; PMCID: PMC6015900.
47. Nie Y, He J, Shirota H, Trivett AL, Yang D, Klinman DM, Oppenheim JJ, ***Chen X**. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. *Sci Signal.* 2018;11(511). Epub 2018/01/04. doi: 10.1126/scisignal.aan0790. PubMed PMID: 29295954; PMCID: PMC8049166.
48. Liu S, ***Chen X**. Dietary therapy may be sufficient for type 1 diabetes treatment. *Cellular & molecular immunology.* 2018;15(2):85-7. Epub 2017/07/12. doi: 10.1038/cmi.2017.56. PubMed PMID: 28690325; PMCID: PMC5811681.
49. Kong X, Zhang Q, Lai Y, Hu H, **Chen X**, Hu Y. Global patent landscape of programmed cell death 1: implications of the rapid expansion. *Expert Opin Ther Pat.* 2018;28(1):69-80. Epub 2017/09/12. doi: 10.1080/13543776.2017.1378349. PubMed PMID: 28891360.
50. He T, Liu S, Chen S, Ye J, Wu X, Bian Z, ***Chen X**. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4⁺Foxp3⁺ Regulatory T Cells. *Front Immunol.* 2018;9:1556. Epub 2018/07/25. doi: 10.3389/fimmu.2018.01556. PubMed PMID: 30038619; PMCID: PMC6046375.
51. Chen K, Tang P, Bao Z, He T, Xiang Y, Gong W, Yoshimura T, Le Y, Tessarollo L, **Chen X**, Wang JM. Deficiency in Fpr2 results in reduced numbers of Lin⁻cKit⁺Sca1⁺ myeloid progenitor cells. *J Biol Chem.* 2018;293(35):13452-63. Epub 20180717. doi: 10.1074/jbc.RA118.002683. PubMed PMID: 30018139; PMCID: PMC6120191.
52. Ahmad S, Azid NA, Boer JC, Lim J, **Chen X**, Plebanski M, Mohamud R. The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review. *Front Immunol.* 2018;9:2572. Epub 2018/11/27. doi: 10.3389/fimmu.2018.02572. PubMed PMID: 30473698; PMCID: PMC6238659.
53. ***Chen X**, Li P, Yang X, Miao X, Luo H. Tumor necrosis factor receptor II (TNFR2) promotes the growth of mouse CT26 colon cancer. *J Immunol.* 2018;200(1 Supplement):178.7-7.
54. Yin T, Kong X, Wang Y, **Chen X**, Hu Y, Shao R. Collaboration networks for R&D of monoclonal antibodies: An analysis based on pipeline projects: United States-China Intellectual Property Institute Inc.; 2017 2017. 135-58 p.
55. Sun L, Liu Z, Wang L, Cun D, Tong HHY, Yan R, **Chen X**, Wang R, Zheng Y. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. *J Control Release.* 2017;254:44-54. Epub 2017/03/28. doi: 10.1016/j.jconrel.2017.03.385. PubMed PMID: 28344018.

56. Nie Y, Yang D, Trivett A, Han Z, Xin H, **Chen X**, Oppenheim JJ. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. *Sci Rep*. 2017;7(1):14186. Epub 2017/10/29. doi: 10.1038/s41598-017-14655-8. PubMed PMID: 29079801; PMCID: PMC5660153.
57. Li P, Zheng Y, **Chen X**. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. *Front Pharmacol*. 2017;8:460. Epub 2017/08/09. doi: 10.3389/fphar.2017.00460. PubMed PMID: 28785220; PMCID: PMC5506195.
58. Lai Y, Wang R, **Chen X**, Tang D, Hu Y, Cai J, Zhang Q, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). *Hum Vaccin Immunother*. 2017;1-10. Epub 2017/03/17. doi: 10.1080/21645515.2017.1286433. PubMed PMID: 28301271.
59. Kong X, Zhang Q, Lai Y, Hu H, **Chen X**, Hu Y. Global patent landscape of programmed cell death 1: implications of the rapid expansion. *Expert Opin Ther Pat*. 2017;1-12. Epub 2017/09/12. doi: 10.1080/13543776.2017.1378349. PubMed PMID: 28891360.
60. Chen X, He T. The p38 MAPK inhibitor SB203580 abrogates TNF-mediated expansion of regulatory T cells. *The Journal of Immunology*. 2017;198(1 Supplement):141.16-16.
61. ***Chen X**, Oppenheim JJ. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. *Sci Signal*. 2017;10(462):1-3. Epub 2017/01/18. doi: 10.1126/scisignal.aal2328. PubMed PMID: 28096506.
62. Zaragoza B, **Chen X**, Oppenheim JJ, Baeyens A, Gregoire S, Chader D, Gorochov G, Miyara M, Salomon BL. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. *Nat Med*. 2016;22(1):16-7. Epub 2016/01/07. doi: 10.1038/nm.4019. PubMed PMID: 26735402; PMCID: PMC6345394.
63. Lee-Chang C, Bodogai M, Moritoh K, **Chen X**, Wersto R, Sen R, Young HA, Croft M, Ferrucci L, Biragyn A. Aging Converts Innate B1a Cells into Potent CD8⁺ T Cell Inducers. *J Immunol*. 2016;196(8):3385-97. Epub 2016/03/18. doi: 10.4049/jimmunol.1502034. PubMed PMID: 26983789; PMCID: PMC4821757.
64. He J, He Z, ***Chen X**. Effects of Chinese medicinal components on chemokine receptors: theory, results and methodology Evidence-based Research Methods for Chinese Medicine. 2016:187-97.
65. ***Chen X**, Oppenheim JJ. Tetrandrine (TET), an immunosuppressive component of Chinese herb, induces tolerogenic dendritic cells and consequently expands regulatory T cells. *Journal of Immunology*. 2016;196:2. PubMed PMID: WOS:000380288303253.
66. ***Chen X**, Oppenheim JJ. Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. *Nat Rev Rheumatol*. 2016;12(11):625-6. Epub 2016/10/21. doi: 10.1038/nrrheum.2016.145. PubMed PMID: 27586383.
67. ***Chen X**, Nie Y, Xiao H, Bian Z, Scarzello AJ, Song NY, Trivett AL, Yang D, Oppenheim JJ. TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. *Sci Rep*. 2016;6:32834. Epub 2016/09/08. doi: 10.1038/srep32834. PubMed PMID: 27601345; PMCID: PMC5013387.
68. Yoshimura T, Liu M, **Chen X**, Li L, Wang JM. Crosstalk between Tumor Cells and Macrophages

in Stroma Renders Tumor Cells as the Primary Source of MCP-1/CCL2 in Lewis Lung Carcinoma. *Front Immunol.* 2015;6(332).

69. Yan F, Du R, Wei F, Zhao H, Yu J, Wang C, Zhan Z, Ding T, Ren X, **Chen X**, Li H. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. *Cancer Immunol Immunother.* 2015;64(11):1475-85. Epub 2015/08/19. doi: 10.1007/s00262-015-1751-z. PubMed PMID: 26280204.

70. Hamano R, Wu X, Wang Y, Oppenheim JJ, ***Chen X**. Characterization of MT-2 cells as a human regulatory T cell-like cell line. *Cellular & molecular immunology.* 2015;12(6):780-2.

71. Geng X, Kong X, Hu H, Chen J, Yang F, Liang H, **Chen X**, Hu Y. Research and development of therapeutic mAbs: An analysis based on pipeline projects. *Hum Vaccin Immunother.* 2015;11(12):2769-76. Epub 2015/07/28. doi: 10.1080/21645515.2015.1074362. PubMed PMID: 26211701; PMCID: PMC4916486.

72. Chen X-p, Tang Z-h, Shi Z, Lu J-j, Su H-x, **Chen X**, Wang Y-t. Current topics on cancer biology and research strategies for anti-cancer traditional Chinese medicine. *Zhongguo Zhong Yao Za Zhi.* 2015;40(17):3416-22. PubMed PMID: 26978983.

73. ***Chen X**, Willette-Brown J, Wu X, Hu Y, Howard OM, Oppenheim JJ. IKK α is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. *FASEB J.* 2015;29(2):443-54.

74. Zhou Q, Hu Y, Howard OM, Oppenheim JJ, ***Chen X**. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4⁺Foxp3⁺ regulatory T cells in vivo. *Cytokine.* 2014;65(1):56-64. Epub 2013/10/02. doi: 10.1016/j.cyto.2013.09.008. PubMed PMID: 24080164; PMCID: PMC3842389.

75. Weiss JM, Subleski JJ, Back T, **Chen X**, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/ α CD40 therapy. *J Immunol.* 2014;192(12):5821-9. Epub 2014/05/09. doi: 10.4049/jimmunol.1400404. PubMed PMID: 24808361; PMCID: PMC4048774.

76. Wei F, Yang D, Tewary P, Li Y, Li S, **Chen X**, Howard OMZ, Bustin M, Oppenheim JJ. The Alarmin HMG1N1 Contributes to Antitumor Immunity and Is a Potent Immunoadjuvant. *Cancer Research.* 2014;74(21):5989-98. doi: 10.1158/0008-5472.Can-13-2042.

77. Hu Y, Xiao H, Shi T, Oppenheim JJ, ***Chen X**. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells. *Immunology.* 2014;142(2):193-201. Epub 2014/01/05. doi: 10.1111/imm.12241. PubMed PMID: 24383743; PMCID: PMC4008227.

78. ***Chen X**, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ. Effective chemoimmunotherapy with anti-TGF β antibody and cyclophosphamide in a mouse model of breast cancer. *PLoS One.* 2014;9(1):e85398. Epub 2014/01/15. doi: 10.1371/journal.pone.0085398. PubMed PMID: 24416401; PMCID: PMC3887137 Dr. John M. McPherson who was a former employee of Genzyme Corporation, and he retired from this company earlier this year. Xin Chen is an employee of Leidos Biomedical Research Inc. (formerly known as SAIC-Frederick), which is a contractor of NCI. This manuscript is not involved in any product and patent from Leidos Biomedical Research Inc. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

79. ***Chen X**, Wakefield LM, Oppenheim JJ. Synergistic antitumor effects of a TGF β inhibitor and cyclophosphamide. *Oncoimmunology*. 2014;3:e28247-e. doi: 10.4161/onci.28247. PubMed PMID: 25050195.
80. ***Chen X**, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. *J Leukoc Biol*. 2014;95(5):723-31. Epub 2014/02/25. doi: 10.1189/jlb.1213633. PubMed PMID: 24563509; PMCID: PMC3984971.
81. ***Chen X**, Wu X, Zhou Q, Howard OM, Netea MG, Oppenheim JJ. TNFR2 is critical for the stabilization of the CD4⁺Foxp3⁺ regulatory T cell phenotype in the inflammatory environment. *J Immunol*. 2013;190(3):1076-84. Epub 2013/01/02. doi: 10.4049/jimmunol.1202659. PubMed PMID: 23277487; PMCID: PMC3552130.
82. ***Chen X**, Willette-Brown J, Wu X, Howard OMZ, Hu Y, Oppenheim J. IKK α is critical for the maintenance of a normal pool of regulatory T cells and for the expansion of both regulatory and effector T cells (P1095). *The Journal of Immunology*. 2013;190(1 Supplement):121.19-.19.
83. ***Chen X**, Wu X, Howard OMZ, Oppenheim J. Interaction of TNF and TNFR2 stabilizes the phenotype and function of CD4⁺FoxP3⁺ regulatory T cells in the inflammatory environment (179.16). *The Journal of Immunology*. 2012;188(1 Supplement):179.16-.16.
84. S G, **Chen X**, JJ O, D M, editors. THE DUAL ROLE OF TNF ON T CELL ACTIVATION. ADVANCES IN TNF FAMILY RESEARCH; 2011 2011: SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY.
85. Hamano R, Huang J, Yoshimura T, Oppenheim JJ, ***Chen X**. TNF optimally activates regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. *Eur J Immunol*. 2011;41(7):2010-20. Epub 2011/04/15. doi: 10.1002/eji.201041205. PubMed PMID: 21491419; PMCID: PMC3783213.
86. Chertov O, Zhang N, **Chen X**, Oppenheim JJ, Lubkowski J, McGrath C, Sowder RC, 2nd, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ. Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture. *PLoS One*. 2011;6(1):e14474. Epub 2011/01/26. doi: 10.1371/journal.pone.0014474. PubMed PMID: 21264298; PMCID: PMC3019152 of Health (NIH), and the NIH was a sponsor of the research work. This does not alter the authors' adherence to all of the PLoS ONE policies on sharing of data and materials.
87. ***Chen X**, Oppenheim JJ. Comment on "Interplay between TNF and Regulatory T Cells in a TNF-Driven Murine Model of Arthritis". *The Journal of Immunology*. 2011;187(4):1527-. doi: 10.4049/jimmunol.1190029.
88. ***Chen X**, Oppenheim JJ. Resolving the identity myth: key markers of functional CD4⁺FoxP3⁺ regulatory T cells. *Int Immunopharmacol*. 2011;11(10):1489-96. Epub 2011/06/04. doi: 10.1016/j.intimp.2011.05.018. PubMed PMID: 21635972; PMCID: PMC3183123.
89. ***Chen X**, Oppenheim JJ. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4⁺FoxP3⁺ regulatory T cells. *Immunology*. 2011;133(4):426-33. Epub 2011/06/03. doi: 10.1111/j.1365-2567.2011.03460.x. PubMed PMID: 21631498; PMCID: PMC3143354.
90. ***Chen X**, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. *FEBS Lett*. 2011;585(23):3611-8. Epub 2011/04/15. doi: 10.1016/j.febslet.2011.04.025. PubMed PMID: 21513711; PMCID: PMC3164898.

91. ***Chen X**, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4⁺FOXP3⁺ regulatory T cells in human peripheral blood. *Eur J Immunol.* 2010;40(4):1099-106. Epub 2010/02/04. doi: 10.1002/eji.200940022. PubMed PMID: 20127680; PMCID: Pmc3096013.
92. ***Chen X**, Oppenheim JJ. TNF- α : an activator of CD4⁺FoxP3⁺TNFR2⁺ regulatory T cells. *Curr Dir Autoimmun.* 2010;11:119-34. Epub 20100218. doi: 10.1159/000289201. PubMed PMID: 20173391; PMCID: PMC6314650.
93. ***Chen X**, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ. Expression of costimulatory TNFR2 induces resistance of CD4⁺FoxP3⁻ conventional T cells to suppression by CD4⁺FoxP3⁺ regulatory T cells. *J Immunol.* 2010;185(1):174-82. Epub 2010/06/08. doi: 10.4049/jimmunol.0903548. PubMed PMID: 20525892.
94. ***Chen X**. Maturation and Activation of Dendritic Cells by Botanicals Used in Traditional Chinese Medicine: Role in Immune Enhancement. In: Watson RR, Zibadi S, Preedy VR, editors. *Dietary Components and Immune Function*. Totowa, NJ: Humana Press; 2010. p. 497-514.
95. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, **Chen X**, Micic D, Alderson K, Murphy WJ, Wiltrout RH. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. *Proc Natl Acad Sci U S A.* 2009;106(46):19455-60. Epub 2009/11/07. doi: 10.1073/pnas.0909474106. PubMed PMID: 19892741; PMCID: PMC2773732.
96. ***Xin Chen**, Oppenheim JJ. Regulatory T cells, Th17 cells and TLRs: implication for autoimmunity and cancer (review). *Pathways.* 2009;10:2-5.
97. Mazzucchelli R, Hixon JA, Spolski R, **Chen X**, Li WQ, Hall VL, Willette-Brown J, Hurwitz AA, Leonard WJ, Durum SK. Development of regulatory T cells requires IL-7R α stimulation by IL-7 or TSLP. *Blood.* 2008;112(8):3283-92. Epub 2008/07/31. doi: 10.1182/blood-2008-02-137414. PubMed PMID: 18664628; PMCID: PMC2569178.
98. Li J, **Chen X**, Lin HS, Oppenheim JJ, Howard OMZ. Inhibitory effect of Sheng Qi Formula (SQF) on Gr-1⁺ CD11b⁺ myeloid immunosuppressor cells (MIC) in the 4T1 murine mammary cancer model. *Cancer Research.* 2008;68(9 Supplement):5336-.
99. Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4⁺CD25⁺FoxP3⁺ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. *J Immunol.* 2008;180(10):6467-71. Epub 2008/05/06. doi: 10.4049/jimmunol.180.10.6467. PubMed PMID: 18453563; PMCID: PMC2699949.
100. ***Xin Chen**, H W. Effects of Traditional Chinese Medicine on Chemokine. . In: HS L, editor. *In Advances in Cancer Research in China: the Therapeutic Effects of Traditional Chinese Medicine on Cancer* (book chapter). Beijing: Beijing University Medical Press; 2008. p. 98-110.
101. Murakami T, **Chen X**, Hase K, Sakamoto A, Nishigaki C, Ohno H. Splenic CD19⁻CD35⁺B220⁺ cells function as an inducer of follicular dendritic cell network formation. *Blood.* 2007;110(4):1215-24. Epub 2007/05/24. doi: 10.1182/blood-2007-01-068387. PubMed PMID: 17519390; PMCID: PMC1939903.
102. Kopf H, de la Rosa GM, Howard OM, ***Chen X**. Rapamycin inhibits differentiation of Th17 cells

and promotes generation of FoxP3⁺ T regulatory cells. *Int Immunopharmacol.* 2007;7(13):1819-24. Epub 2007/11/13. doi: 10.1016/j.intimp.2007.08.027. PubMed PMID: 17996694; PMCID: PMC2223142.

103. Kim JY, Kim HJ, Hurt EM, **Chen X**, Howard OMZ, Farrar WL. Functional and genomic analyses of FOXP3⁻ transduced Jurkat-T cells as regulatory T (Treg)-like cells. *Biochem Biophys Res Commun.* 2007;362(1):44-50. Epub 2007/08/21. doi: 10.1016/j.bbrc.2007.07.187. PubMed PMID: 17706604.

104. Howard OMZ, Oppenheim JJ, ***Chen X**. Biological Regulators of CD4⁺CD25⁺FOXP3⁺ Regulatory T-cells. *Cytokine.* 2007;39(1):16. doi: <https://doi.org/10.1016/j.cyto.2007.07.061>.

105. Hodge DL, Berthet C, Subleski J, Pascal V, Bere W, **Chen X**, Buschman M, Wolfe T, Young HA. Challenging Evolution: Eliminating the IFN-gamma 3 ARE Effects T Cell Homeostasis. *Cytokine.* 2007;39(1):15-6. doi: <https://doi.org/10.1016/j.cyto.2007.07.059>.

106. Hodge D, Berthet C, Subleski J, Pascal V, Bere W, **Chen X**, Buschman M, Wolfe T, Young H. Phenotypic changes in IFN-gamma 3'UTR are knock out mice 2007 2007-08.

107. ***Chen X**, Howard OM, Oppenheim JJ. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4⁺ cells. *J Immunol.* 2007;178(10):6123-9. Epub 2007/05/04. doi: 10.4049/jimmunol.178.10.6123. PubMed PMID: 17475838.

108. ***Chen X**, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4⁺CD25⁺ T regulatory cells. *J Immunol.* 2007;179(1):154-61. Epub 2007/06/21. PubMed PMID: 17579033.

109. ***Chen X**, Yang L, Howard OM, Oppenheim JJ. Dendritic cells as a pharmacological target of traditional Chinese medicine. *Cellular & molecular immunology.* 2006;3(6):401-10. Epub 2007/01/30. PubMed PMID: 17257493.

110. ***Chen X**, Winkler-Pickett RT, Carbonetti NH, Ortaldo JR, Oppenheim JJ, Howard OM. Pertussis toxin as an adjuvant suppresses the number and function of CD4⁺CD25⁺ T regulatory cells. *Eur J Immunol.* 2006;36(3):671-80. Epub 2006/02/16. doi: 10.1002/eji.200535353. PubMed PMID: 16479542; PMCID: PMC3153960.

111. ***Chen X**, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3⁺CD4⁺CD25⁺ T regulatory cells in vivo and enhances their capacity to suppress EAE. *Eur J Immunol.* 2006;36(8):2139-49. Epub 2006/07/15. doi: 10.1002/eji.200635873. PubMed PMID: 16841298.

112. 曾广仙, **陈新**, 刘俊英, 衷学军, 代丽红, 赵璐, 沈关心. 加味玉屏风散对创伤应激小鼠细胞免疫功能的影响. *中医杂志.* 2005;46(5):3.

113. 曾广仙, 刘俊英, 熊金蓉, 代丽红, 赵璐, 杨燕萍, **陈新**, 沈关心. 加味玉屏风散对创伤应激小鼠 CD4⁺CD25⁺调节性 T 细胞影响的实验研究. *中华微生物学和免疫学杂志.* 2005;25(1):69-.

114. Krakauer T, **Chen X**, Howard OM, Young HA. Triptolide attenuates endotoxin- and staphylococcal exotoxin-induced T-cell proliferation and production of cytokines and chemokines. *Immunopharmacol Immunotoxicol.* 2005;27(1):53-66. Epub 2005/04/05. doi: 10.1081/iph-51294. PubMed PMID: 15803859.

115. Howard OM, Dong HF, Su SB, Caspi RR, **Chen X**, Plotz P, Oppenheim JJ. Autoantigens signal

through chemokine receptors: uveitis antigens induce CXCR3⁻ and CXCR5⁻ expressing lymphocytes and immature dendritic cells to migrate. *Blood*. 2005;105(11):4207-14. Epub 2005/02/17. doi: 10.1182/blood-2004-07-2697. PubMed PMID: 15713799; PMCID: PMC1895027.

116. ***Chen X**, Oppenheim JJ, Howard OM. BALB/c mice have more CD4⁺CD25⁺ T regulatory cells and show greater susceptibility to suppression of their CD4⁺CD25⁻ responder T cells than C57BL/6 mice. *J Leukoc Biol*. 2005;78(1):114-21. Epub 2005/04/23. doi: 10.1189/jlb.0604341. PubMed PMID: 15845645.

117. ***Chen X**, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. *Blood*. 2005;106(7):2409-16. Epub 2005/06/16. doi: 10.1182/blood-2005-03-0854. PubMed PMID: 15956285; PMCID: Pmc1569904.

118. Chung IY, Dong HF, Zhang X, Hassanein NM, Howard OM, Oppenheim JJ, ***Chen X**. Effects of IL-7 and dexamethasone: induction of CD25, the high affinity IL-2 receptor, on human CD4⁺ cells. *Cell Immunol*. 2004;232(1-2):57-63. Epub 2005/06/01. doi: 10.1016/j.cellimm.2005.01.011. PubMed PMID: 15922716.

119. ***Chen X**, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. *Cellular & molecular immunology*. 2004;1(5):336-42. Epub 2005/11/16. PubMed PMID: 16285892.

120. ***Chen X**, Murakami T, Oppenheim JJ, Howard OMZ. Differential response of murine CD4⁺CD25⁺ and CD4⁺CD25⁻ T cells to dexamethasone-induced cell death. *Eur J Immunol*. 2004;34(3):859-69. Epub 2004/03/03. doi: 10.1002/eji.200324506. PubMed PMID: 14991616.

121. ***Chen X**, Krakauer T, Oppenheim JJ, Howard OM. Yin zi huang, an injectable multicomponent chinese herbal medicine, is a potent inhibitor of T-cell activation. *J Altern Complement Med*. 2004;10(3):519-26. Epub 2004/07/16. doi: 10.1089/1075553041323687. PubMed PMID: 15253857.

122. 曾广仙, **陈新**, 刘俊英, 沈关心, 熊金蓉. 加味玉屏风汤对创伤应激小鼠 IL-2 与 IL-2R 基因表达的影响. *实用临床医学 (湖北)*. 2003;17(2):2.

123. Krakauer T, **Chen X**, Howard OM, Young HA. RNase protection assay for the study of the differential effects of therapeutic agents in suppressing staphylococcal enterotoxin B-induced cytokines in human peripheral blood mononuclear cells. *Methods Mol Biol*. 2003;214:151-64. Epub 2002/12/20. doi: 10.1385/1-59259-367-4:151. PubMed PMID: 12489461.

124. ***Chen X**, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C, Oppenheim JJ, Howard OM. Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. *Antimicrob Agents Chemother*. 2003;47(9):2810-6. Epub 2003/08/26. PubMed PMID: 12936978; PMCID: Pmc182643.

125. ***Chen X**, Beutler JA, McCloud TG, Loehfelm A, Yang L, Dong HF, Chertov OY, Salcedo R, Oppenheim JJ, Howard OM. Tannic acid is an inhibitor of CXCL12 (SDF-1 α)/CXCR4 with antiangiogenic activity. *Clin Cancer Res*. 2003;9(8):3115-23. Epub 2003/08/13. PubMed PMID: 12912963.

126. 杨燕萍, 段登志, 胡冬根, **陈新**, 未炎, 李小慧. 加味玉屏风汤对小鼠胸腺细胞凋亡的抑制作用.

中国中西医结合杂志. 2002;22(9):3.

127. ***Chen X**, Yang L, Oppenheim JJ, Howard MZ. Cellular pharmacology studies of shikonin derivatives. *Phytother Res*. 2002;16(3):199-209. Epub 2002/08/08. doi: 10.1002/ptr.1100. PubMed PMID: 12164262.

128. ***Chen X**, Mellon RD, Yang L, Dong H, Oppenheim JJ, Howard OM. Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niu Huang, on human leukocyte response to chemoattractants. *Biochem Pharmacol*. 2002;63(3):533-41. Epub 2002/02/21. PubMed PMID: 11853704.

129. ***Chen X**, Howard OM, Yang X, Wang L, Oppenheim JJ, Krakauer T. Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. *Life Sci*. 2002;70(24):2897-913. Epub 2002/09/25. PubMed PMID: 12269401.

130. 杨燕萍, 胡冬根, **陈新**, 朱炎, 胡作为. 黄芪多糖对小鼠胸腺细胞凋亡的调节作用. *中华微生物学和免疫学杂志*. 2001;21(6):1.

131. 杨燕萍, 胡冬根, **陈新**. 黄芪多糖和加味玉屏风汤对小鼠胸腺细胞凋亡抑制作用的比较. *湖北中医学院学报*. 2001;003(004):34-5.

132. ***Chen X**, Oppenheim J, Howard OM. Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1. *Int Immunopharmacol*. 2001;1(2):229-36. Epub 2001/05/22. doi: 10.1016/s1567-5769(00)00033-3. PubMed PMID: 11360924.

133. Yang D, Chen Q, Stoll S, **Chen X**, Howard OM, Oppenheim JJ. Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: correlation with receptor expression. *J Immunol*. 2000;165(5):2694-702.

134. ***陈新**, 杨路, 曾广仙, 沈关心, 毛树章. The regulatory action of the modified Yu Ping Feng Tang on cellular immunity in mice under amputation-induced stress. *中医杂志: 英文版*. 2000(4):5.

135. ***陈新**. 加味玉屏风汤及黄芪多糖对胸腺细胞凋亡影响的实验研究: 湖北中医学院 湖北中医药大学; 2000.

136. ***Chen X**, Yang L, Zeng G, Shen G. The regulatory action of the modified Yu Ping Feng Tang on cellular immunity in mice under amputation-induced stress. *J Tradit Chin Med*. 2000;20(4):302-6. Epub 2001/03/27. PubMed PMID: 11263289.

137. ***Chen X**, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ, Howard MZ. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. *Inflamm Res*. 2000;49(12):744-55. Epub 2001/02/24. PubMed PMID: 11211928.

138. ***陈新**, 杨路, 夏志道. 玉屏风颗粒剂对手术患者免疫功能调节作用的临床研究. *中药新药与临床药理*. 1999;10(4):199-202.

139. 区永欣, 王洪琪, 邝杰钊, 吴弥漫, **陈新**, 温伟强, 陈革新, 杨培鑫, 温素萍, 傅杰英. 卫气病理生理研究. *医学研究杂志*. 1998(12):2.

140. 刘菊芳, 王俊玲, 陈新, 潘桂琼. 补肾调肝敛乳方治疗高泌乳素血症的临床研究. 中国中西医结合杂志. 1998;18(3):3.
141. *陈新, 杨路, 白云. 加味玉屏风对截肢应激大鼠血浆 ACTH 及皮质酮的影响. 河北中西医结合杂志. 1998;7(7):2.
142. *陈新, 杨路, 曾广仙, 沈关心. 加味玉屏风汤对截肢应激小鼠细胞免疫功能的调节作用. 中医杂志. 1998;39(12):3.
143. *陈新, 杨路. 吴国祥验案四则. 湖北中医杂志. 1998;04:48-.
144. *陈新, 区永欣, 陈洁文. 亚急性风寒环境刺激对小鼠胸腺的影响及其机理探讨. 中国中医药科技. 1998;5(3):2.
145. *陈新, 刘菊芳, 桂耀庭, 张永锋. 补肾调肝敛乳方对泌乳素分泌影响的动物实验研究. 中国实验方剂学杂志. 1998;4(3):3.
146. *陈新. 亚急性风寒环境刺激对小鼠免疫功能影响. 中国中医基础医学杂志. 1998;4(3):3.
147. 刘菊芳, *陈新. 中医药治疗高泌乳素血症的研究进展. 中国医药学报. 1997.
148. *陈新, 白云, 杨路, editors. 加味玉屏风汤及黄芪多糖对对应激小鼠应激激素及巨噬细胞功能的调节作用. 世界中西医结合大会; 1997.
149. *陈新, 杨路, 白云. 加味玉屏风汤对截肢应激小鼠巨噬细胞功能的调节作用. 中医研究. 1997;10(6):4.
150. 李伯南, *陈新. 加味玉屏风散对手术应激小鼠胸腺超微结构的影响. 中国病理生理杂志. 1996;12(2):178-80.
151. 刘菊芳, 陈新, 桂耀庭. 补肾调肝敛乳方治疗高泌乳素血症的实验研究. 中药新药与临床药理. 1996;7(2):3.
152. *陈新, 张永峰. 加味玉屏风汤对对应激及激素注射小鼠细胞免疫功能的影响. 中国实验临床免疫学杂志. 1996(第 3 期):42-4.
153. 杨路, *陈新. 关于六淫概念的讨论. 湖北中医杂志. 1993;15(4):2.
154. *陈新, 陈峰. 环境寒冷因素对免疫功能的影响. 深圳医学信息. 1993(2):2.
155. *陈新, 区永欣. 玉屏风散对人工风寒气象环境介导小鼠免疫抑制的预... 中国实验临床免疫学杂志. 1993;5(5):4.
156. *陈新, 区永欣. 玉屏风散对风寒因素介导小鼠巨噬细胞免疫功能抑制的预防作用. 实用中西医结合杂志. 1993;6(9):548-9.
157. *陈新, 区永欣. 人工风寒环境对小鼠单核巨噬细胞系统吞噬功能的影响. 中国中西医结合杂志. 1993;013(012):739-40.

158. *陈新. PM ϕ 释放 H_2O_2 量测定方法的改进及其在中医免疫药理研究中的应用. 广西中医药. 1993;16(5):2.

Conference Presentation and invited talk

1. miR-125b-5p Sensitizes Anti-PD-L1 Therapy by Enhancing Anti-tumor Immune Responses. 2023 SLB Annual Meeting: Future of Immunology-New Solutions for Old Problems. University of Georgia, Athens, GA, USA. Sept 17-30, 2023
2. Targeting of TNFR2 in the treatment of colitis. Centre for Chinese Herbal Medicine Drug Development Limited, HKBU. Hong Kong, China. 11 Aug 2023.
3. Chinese herb-derived naturally occurring compounds act on TNFR2 and its therapeutic implications. International Symposium on Innovation of Traditional Chinese Medicine and Natural Product Resources in the Asia-Pacific Region, Tianjin, China. Aug 26-28, 2023.
4. 針對腫瘤壞死因子受體 TNFR2 靶點的腫瘤免疫療法. FDCT. Macau, China. 10 Jul 2023.
5. TNFR2 對調節性 T 細胞的決定性調節作用及其治療學意義. 中国科学院广州生物医药与健康研究院联合生命科学学院 细胞命运调控与疾病粤港澳联合实验室建设研讨会. Guangzhou, Guangdong, China. 27 Jun 2023.
6. 從六淫致病機理研究到藥物作用新靶點的發現. 廣東省中醫院建院 60 周年系列學術活動. Guangdong, China. 17 Jun 2023.
7. TNFR2-targeting peptide for cancer immunotherapy. Immunology 2023 (American Association of Immunologists, AAI, 2023 annual meeting). Washington DC, USA. May 11-15, 2023.
8. Targeting TNFR2 in cancer immunotherapy. Nantong University. Jiangsu, Nantong, China. 26 May 2023.
9. TNFR2 in activation of Tregs. 30 Years of the CIG, a Tribute to Joost Oppenheim: From Lymphodrek to defined molecules: cytokines, alarmins, and chemokines. NIH, Bethesda, MD, USA. 27 Mar 2023.
10. TNFR2 是中藥免疫調節作用的新靶點. 第五届广东省中西医结合学会学术大会暨岭南中西医结合医学研究与转化高峰论坛 冠心病論壇. Guangzhou, China. 26 Feb 2023.

11. TNFR2 is a novel target of immunoregulatory Chinese medicine. ICMS Faculty Seminar Series. Macau, China. 10 Jan 2023.
12. 靶向 TNFR2 腫瘤免疫治療：近期進展. 粵港澳腸道微生態論壇. Guangzhou, China. 06 Jan 2023.
13. 澳門大學中西合璧的藥學教育. 2022 華西臨床藥學論壇. Chengdu, China. 18 Dec 2022.
14. 靶向 TNFR2 腫瘤免疫治療研究的新進展. 第十一屆全國生物治療大會. Tianjin, China. 10 Dec 2022.
15. TNFR2 as a target for cancer immunotherapy: recent evidence. 澳門 MSCO 年會. Macau, China. 10 Dec 2022.
16. A novel mechanism of immunoregulatory activity of Chinese medicine. The 4th Sino-CPLP Symposium on Natural Medicine and Biodiversity Resources (SNMBR) & the International Forum on Research and Development of Traditional Chinese Medicine Industry. Macau, China. 02 Dec 2022.
17. 从中医“风寒”致病理论到肿瘤免疫治疗新靶点的发现. 華創會. Wuhan, China. 16 Nov 2022.
18. TNFR2：免疫調節作用的新藥物靶點. 創新藥物研究交流會. Fuzhou, Fujian, China. 24 Oct 2022.
19. TNFR2：中藥免疫調節作用的新靶點. 20 周年院庆. Macau, China. 22 Oct 2022.
20. MiR-125b-5p modulates the function of Tregs by targeting TNFR2. Engaging For Impact in Cancer-Cancer Conference in Melbourne. Melbourne, Australia. 21 Sep 2022.
21. 中藥靶向 TNFR2: 在腫瘤及自身免疫性疾病治療中的作用. 中华中医药学会免疫学分会第八次学术会议. Guangzhou China. 17 Sep 2022.
22. 靶向 TNFR2 小分子新型腫瘤免疫治療藥物的研發. 上海科技基金. Shanghai, China. Jun 2022.
23. TNFR2：一个中樞神經系統炎症性疾病治療新靶標. 廣東中西醫結合神經年會. Guangdong, China. 14 Feb 2022.
24. Targeting of TNFR2 in the treatment of cancer. Roche Innovation Center China. Shanghai, China. 14 Feb 2022.
25. 从《黄帝内经》病因理论到 TNFR2 作為腫瘤和自身免疫性疾病治療靶點的發現. 哈尔滨医科大学. Heilongjiang, Haerbin, China. 06 Dec 2022.

26. 從卓越科學研究到助力澳門經濟多元發展-澳门大学中华医药研究院 20 年的歷程. 2022 港澳台科技人才创新创业交流暨专利成果推介. Hubei, Wuhan, China. 08 Dec 2022.
27. R&D of small molecule TNFR2 inhibitors (SMTR2i) for cancer treatment. 2022 国际产学研用合作会议海南分论坛. Hainan, China. 8 Dec 2022.
28. TNFR2: new target for cancer precision treatment. First Jiangsu-Hong Kong-Macau Forum Biomedical and Pharmaceutical Science Forum. Nanjing, Jiangsu, China. 17 Dec 2021.
29. TNFR2 is A Target of Chinese herb-derived Small Molecule Compounds. ZCMU-UM Innovation Forum of Chinese Medicine. Hangzhou/Macau, China. 13 Nov 2021.
30. IDENTIFICATION OF TNFR2-TARGETING COMPOUNDS FROM TRADITIONAL CHINESE HERBS. 2021 Annual Meeting of Coronary Heart Disease Professional Committee of Guangdong Society of Integrative Medicine and the 18th Cardiovascular Evidence-based Medicine. Guangzhou, Guangdong, China. 5-6 Nov 2021.
31. TNFR2, New target for cancer immunotherapy. The 2nd Frontier Forums on Synthetic Immunology. Shenzhen, Guangdong, China. 11 Nov 2021
32. TNFR2: new target for cancer precision treatment. The 6th International Conference on Cancer Precision Medicine. Haikou, Hainan, China. 6 Nov 2021
33. Chinese Medicine regulates immune responses: cellular and molecular basis. 2021 University Horizon Program-Chengdu University of Chinese Medicine. Chengdu, Sichuan, China. 6 Nov 2021
34. Immune regulation and cancer immunology. 2021 University Horizon Program-Chengdu University of Chinese Medicine. Chengdu, Sichuan, China. 31 Oct 2021
35. Targeting of TNFR2 in the treatment of cancer and autoimmune diseases. Distinguished Lecture Series, Centre for Chinese Herbal Medicine Drug Development (CDD), Hong Kong SAR, China. 21 Aug 2021.
36. TNFR2: emerging new target for cancer immunotherapy. South China Summit for Immunology and Disease. Zhuhai, Guangdong, China. 7-8 Aug 2021
37. Regulate immune responses in the treatment and prevention of COVID-19. Chinese Culture Center, University of Macau. Macau SAR, China. 14 Dec 2020.
38. From etiology in Chinese Medicine to TNFR2: immunology research experiences for an acupuncturist. Development and prospect of acupuncture and moxibustion evidence-

based medicine in the new era (China Society of Acupuncture. Shenzhen, Gungdong, China. 18 Oct, 2020.

39. Regulation and Quality Management of Traditional Chinese Medicine (TCM) Products in Macao. First WHO Interregional training workshop: ensuring quality of TCI products (Online). 14-16 Oct, 2020.
40. Targeting of TNFR2 in cancer treatment: kill two birds with one stone. 2020 annual meeting of Macau society of clinical oncology. Macao SAR, China. Dec 19, 2020
41. The role of TNFR2 in colon inflammation and colon cancer. The 3rd Guangdong-Hong Kong-Macao Symposium on Gut Microbiota. Guangzhou, Guangdong, China. Nov 6-8, 2020.
42. AXIS OF MEMBRANE BOUND TNF-TNFR2 IS A TARGET OF ANTI-INFLAMMATORY AGENTS DERIVED FROM CHINESE MEDICINE. Institute of Integrated Chinese and Western Medicine. Sun Yat-sen University. Guangzhou, Guangdong, China. 29 Nov, 2020.
43. The decisive role of TNFR2 in the activation and expansion of regulatory T cells: clinical and therapeutic implications. 2020 Wuhan Symposium on Immunology in Respiratory Critical Medicine. Wuhan, Hubei, China July 4, 2020.
44. Natural occurring small molecule TNFR2 inhibitor as a novel immunotherapeutic agent in cancer treatment. 3rd Lingnan Conference of Pharmaceutical Sciences. Guangzhou, Guangdong, China. Nov 30-Dec 2, 2019
45. Implications of TNFR2 in the cancer treatment with integrative medicine. Guangdong Integrative Oncology Meeting. Guangdong Association of Integrative Medicine Oncology Committee. Guangzhou, China. Nov 15-17, 2019.
46. Targeting of TNFR2+ Tregs: new strategy for cancer treatment with integrative medicine . 2019 International Symposium of Integrative Oncology. Korean Society of Integrative Oncology. Seoul, South Korea. Nov 9-11, 2019
47. Decisive role of TNFR2 singling in Treg activation and its therapeutic implications. Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine. Shanghai, China. Oct 29, 2019.
48. TNFR2 plays a decisive role in Treg biology: implications in the treatment of cancer and autoimmune diseases. Hong Kong Immunology Forum 2019 (organized by Hong Kong Society for Immunology and LKS Faculty of Medicine, HKU). Oct 12, 2019.
49. TNF and TNFR2: emerging target for precision cancer treatment with Chinese medicine. Precision and Integrative Oncology Meeting. Guangdong Association of Chinese Medicine. Guangzhou, Guangdong, China. Sept 28, 2019

50. TNFR2 is an emerging target of cancer immunotherapy. 15th National Congress of Laboratory Medicine (Chinese Medical Association and Chinese Society of Laboratory Medicine). Suzhou, Jiangsu, Aug 29-31.
51. Targeting of TNFR2 is a novel mechanism of immune regulatory effect of Chinese medicine. The 5th National Conference of Chinese Medicine-Immunology (China Association of Chinese Medicine). Aug 24-25, Guangzhou, Guangdong, China.
52. Regulation of immune responses: eastern and western approaches. Institute of Integrative Medicine. Sun Yat-sen University. Guangzhou, Guangdong, China. Aug 23, 2019.
53. Elimination of highly suppressive tumor-associated TNFR2+ Tregs: a new revenue of cancer immunotherapy with Chinese medicine. 2019 International Consortium for Chinese Medicine and Cancer (ICCMC) Symposium. Aug 15-17. Hangzhou, Zhejiang, China.
54. Targeting of TNFR2 is a novel mechanism of immune regulatory effect of Chinese medicine. Chengdu, Sichuan, China. 10th National Conference of Chinese Medicine and Immunology (Chinese Society for Immunology). July 18-20, 2019.
55. TNFR2 is emerging target of cancer precision immunotherapy. NSFC-FDCT Joint Symposium for Precision Medicine. Macau SAR, China. June 25-27, 2019.
56. Small Molecule inhibitor of TNFR2 in Cancer Immunotherapy. Cancer Immunotherapy Symposium. School of Pharmaceutical Sciences, Sun Yat-sen University. Guangzhou, Guangdong, China. June 12, 2019.
57. Two pore channel inhibitor tetrandrine promotes TNF-TNFR2 interaction and consequently stimulates proliferative expansion of CD4⁺Foxp3⁺ regulatory T cells. Innate Immune Receptors: Roles in Immunology and Beyond (M1, Keystone Symposium). Taipei, Taiwan. Mar 10-14, 2019.
58. Acupressure. Choi Kei Yau College. University of Macau. Macau SAR, China. Jan 29, 2019.
59. TNFR2 is emerging target of cancer immunotherapy. School of Medicine. Zhejiang University. Hangzhou, Zhejiang, China. Jan 18, 2019.
60. The practice and research of Chinese Medicine in the USA. Bay Area Forum of Chinese Medicine. Macau SAR, China. Nov 4, 2018.
61. Targeting TNFR2 for cancer immunotherapy. The 7th Cross Strait Immunology Summit. Macau University of Science and Technology. Macau SAR, China. Oct. 12-15, 2018.

62. Regulation of Immune Responses: Eastern and Western Approaches. China Pharmaceutical University. Nanjing, Jiangsu Province, China. July 20, 2018.
63. Acupuncture, Meridians and Science. Hou Kong Middle School, Macau SAR. July 7, 2018.
64. Targeting of TNFR2 in the immunotherapy of cancer. 1st Guangdong-HK-Macau Bay Area Cancer Immunotherapy Summit. Hengqing, Zhuhai, Guangdong, China. June 30, 2018.
65. Tumor necrosis factor receptor II (TNFR2) promotes the growth of mouse CT26 colon cancer. AAI (American Association of Immunologists) 2018 Annual Meeting. Austin, Texas, USA, 4-8 May, 2018.
66. Regulation of immune cells by CM: Trans-cultural study from CM school to US NCI/NIH. 9th National Forum of PhD student in Chinese Medicine. Hubei University of Chinese Medicine, Wuhan, Hubei, China. April 3, 2018
67. Acupressure. Shiu Pong College, University of Macau. Mar 23, 2018.
68. TNFR2 is an emerging target in cancer immunotherapy. Biomedical Translational Research Institute, Jinan University, Guangzhou, Guangdong, China. Jan 20, 2018.
69. The decisive role of TNF-TNFR2 in the activation and expansion of Treg cells: implications in cancer immunotherapy. Xiehe Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China. Dec 14, 2017.
70. The decisive role of TNF-TNFR2 pathway in the activation of CD4⁺Foxp3⁺ regulatory T cells: implications in tumor immunotherapy. Leukocytebiology 2017 (2017 Society of Leukocyte Biology 50th Anniversary Meeting). Vancouver, Canada. Oct. 5-7, 2017.
71. Chinese herbs may enhance anti-tumor immune responses by blocking TNFR2. 2017 International Consortium for Chinese Medicine and Cancer (ICCMS). Guangzhou, China. August 15-17, 2017.
72. Acupuncture: theory, practice and science. WHO workshop on traditional medicine. Macau SAR, China. July 9, 2017.
73. TNFR2 is an emerging target in cancer immunotherapy. NSFC-FDCT Cancer Symposium. Guangzhou, China. June 20, 2017
74. Acupuncture: ancient Chinese wisdom help you stay healthy. Affiliation School of University of Macau. Macau SAR, China. March 30, 2017.

75. p38 MAPK inhibitor SB203580 abrogated TNF-mediated expansion of regulatory T cells. AAI (American Association of Immunologists) 2017 Annual Meeting. Washington DC. May 12-16, 2017.
76. Relieving pain with acupuncture: the scientific evidence. TEDxUniversityofMacau 2017. University of Macau. Jan 21, 2017.
77. Decisive role of TNF (Tumor Necrosis Factor) in the function of immunosuppressive cells and its therapeutic implications. Faculty of Health Sciences, University of Macau. Feb 10, 2017
78. TNF-TNFR2 pathways in inducing and breaking immune tolerance. Shenzhen 2nd People's Hospital. Shenzhen, China. Nov. 3, 2016.
79. CD4+Foxp3+ regulatory T cells: theory and methodology. Shenzhen Chinese Medical Hospital. Shenzhen, China. Nov. 2, 2016.
80. Yin and Yang of TNF in tumor immunotherapy. Greater China TCM Summit. Longgang, Shenzhen. Oct. 23, 2016.
81. Yin and Yang of Tumor Necrosis Factor: Homeostatic Concept of Traditional Chinese Medicine in Cancer Immunotherapy. The 4th Annual Conference of Specialty Committee of Oncology of World Federation of Chinese Medicine Societies. Beijing, China. Oct 21-22, 2016.
82. TNFR2-expressing Tregs in Tumor Immunology: potential for More Precise Tumor Immunotherapy. Greater China Prevision Medicine Symposium. Lylin Villa. Shenzhen, China. Oct. 12-14, 2016.
83. Ying and Yang of Tumor Necrosis Factor in Tumor Immunotherapy. Greater China Chinese Medicine Summit. Longgang, Shenzhen, China. Oct. 23, 2016.
84. TNF-TNFR2 interaction activates and expands Tregs: implications in cancer immunotherapy. Ling Nan Clinical Immunology Summit. Sept 3-4, 2016. Guangzhou, China.
85. Targeting of TNFR2 is a novel strategy in cancer immunotherapy (oral presentation). 3rd Macau Symposium on Biomedical Sciences 2016. University of Macau. May 23-24, 2016.
86. Tetrandrine (TET), an immunosuppressive component of Chinese herb, induces tolerogenic dendritic cells and consequently expands regulatory T cells (poster presentation). AAI (American Association of Immunologists) 2016 Annual Meeting. Seattle. May 13-17, 2016.

87. Targeting Major Components of Immune Response by Traditional Chinese Medicines: A Trans-cultural Study At US National Cancer Institute. International Conference on Cutting-Edge Pharmacology: Contemporary Issues and Future Challenges” (IPSCON-2015). Rajkot, India. Dec 17-21, 2015.
88. Identification of novel immune regulators from Chinese medicine: implication in the discovery of new therapeutics. Macau Forum of Chinese medicine. University of Macau, Macau SAR, China. Nov. 29, 2015.
89. Regulation of immune cells: trans-cultural study from GZUCM to NCI/NIH. Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. Nov. 27, 2015
90. TNF-TNFR2 pathway is novel target in cancer immunotherapy: implications in the study of Chinese medicine. Medical School Shenzhen University. Shenzhen, China. Nov. 3, 2015
91. Targeting TNF-TNFR2 pathway is a novel strategy in cancer immunotherapy: implications in the study of anti-cancer Chinese medicine. 2015 International Symposium on Consortium for Chinese Medicine and Cancer. Dalian, Liaoning, China. Oct. 16, 2015-18 Oct. 2015
92. Targeting Major Components of Immune Response by Traditional Chinese Medicines: A Trans-cultural Study At US National Cancer Institute. The 8th National Conference of Chinese Medicinal Immunology. Zhenzhou, Henan, China. 18 Sept. 2015-21 Sept. 2015
93. TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. 7th International Conference on Autoimmunity. Chania, Greece. 29 Sept. 2015-4 Oct. 2015.
94. Role of TNF-TNFR2 pathway is the protective and pathogenic immune responses in colitis. Hong Kong-Macau Colitis Symposium. Hong Kong Baptist University. April 10, 2015. HKBU, Hong Kong SAR, China.
95. Role of TNF-TNFR2 pathway is the protective and pathogenic immune responses in colitis. Hong Kong-Macau Colitis Symposium. Hong Kong Baptist University. April 10, 2015. HKBU, Hong Kong SAR, China.
96. Targeting TNF-TNFR2 pathway is a novel strategy in cancer immunotherapy. Biopharmaceutical Innovation and Development-from Bench to Bed. Shanghai Jiaotong University. Shanghai, China. March 30, 2015.
97. Induction of tolerogenic dendritic cells (DCs) by a Chinese herbal component. Laboratory of Molecular Immunoregulation. CIP, CCR, NCI, NIH. Feb 24, 2015.
98. Regulation of Chinese medicine on immune system. Shenzhen 2nd Peoples Hospital. Shenzhen, China. Dec. 25, 2014

99. Regulation of regulators. Shenzhen 2nd Peoples Hospital. Shenzhen, China. Dec. 25, 2014
100. Modulation of Chinese Medicine on major components of immune system: implications in the development of new therapeutics. Macau Forum on Chinese Medical Sciences. Taipa, Macau. Nov., 27, 2014.
101. TNF-TNFR2 interaction activates immunosuppressive CD4+Foxp3+ regulatory T cells: implications for tumor immunotherapy. 7th National Biotherapy Conference. Shanghai, China. Oct 24~26, 2014.
102. Cyclophosphamide and anti-TGF β antibody synergistically enhanced the immunogenicity and efficacy of a cancer cell vaccine in a mouse breast cancer model. CANCER IMMUNOLOGY AND IMMUNOTHERAPY: Delivering the Promise. NIH, Bethesda. Oct. 9-10, 2014.
103. An Overview of Chinese Acupuncture: Theory, Practice and Sciences. NCCAM, NIH. Bethesda, MD. Sept 22, 2014
104. Pharmacological and biological modulation of Treg cells. Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (FDA). Bethesda, MD. May 27, 2014.
105. TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. *AAI (American Association of Immunologists) 2014 Annual Meeting*. Pittsburgh, PA. May 2-6, 2014.
106. Tumor necrosis factor (TNF): a link between tumor inflammation and tumor immunosuppression. *AATCM Symposium*. Columbia, MD. Oct. 27, 2013.
107. Effective chemoimmunotherapy with anti-TGF β antibody and cyclophosphamide in a mouse model of breast cancer. *AACR (American Association of Cancer Research) 2013 Annual Meeting*. Washington DC. April 6-10, 2013.
108. IKK α is critical for the maintenance of a normal pool of regulatory T cells and for the expansion of both regulatory and effector T cells. *AAI (American Association of Immunologists) 2013 Annual Meeting*. Honolulu, Hawaii. May 3-7, 2013.
109. Successful chemoimmunotherapy with anti-TGF β antibody and cyclophosphamide on breast cancer in mice. *Frontiers in Basic Immunology 2012*. Oct. 4-5, 2012.
110. Critical role for TNFR2 in the phenotypic stabilization and function of CD4+FoxP3+ regulatory T cells in the inflammatory environment. *TNF cytokine biology and signaling symposium*. NIH, Bethesda, MD. May 24, 2012.

111. Interaction of TNF and TNFR2 stabilizes the phenotype and function of CD4⁺FoxP3⁺ regulatory T cells in the inflammatory environment. *AAI (American Association of Immunologists) 2012 Annual Meeting*. Boston, MA. May 4-8, 2012.
112. From research to publication: the experiences of a Traditional Chinese medical doctor in NCI/NIH. *4th International Congress of TCM and Integrated TCM-WM Oncology*. Nanning, Guangxi, China. April 13-15, 2012.
113. Does traditional Chinese medicine regulate immune system? Shenzhen Hospital of Chinese Medicine. Shenzhen, China. April 13, 2012
114. Pharmacological and biological regulation of CD4⁺FoxP3⁺ regulatory T cells. School of Chinese Medicine, Hong Kong Baptist University. Hong Kong, China. April 12, 2012
115. TNF by inducing co-stimulatory TNF receptor superfamily members TNFR2, 4-1BB and OX40 augments the number and function of CD4⁺FoxP3⁺ regulatory T cells. *Keystone Symposium: Immunoregulation Network*. Breckenridge, Colorado April 1 - 6, 2011.
116. Interaction between Tumor Necrosis Factor and Tumor Necrosis Factor Type II Receptor preferentially activates CD4⁺FoxP3⁺ regulatory T cells: Implications in tumor immunotherapy. *3rd International Congress of Chinese medicine and Integrative Chinese and Western medicine Oncology*. Ningbo, China. June 10~12, 2010.
117. Expression of co-stimulatory TNFR2 enhances resistance of CD4⁺FoxP3⁻ conventional T cells to suppression by CD4⁺FoxP3⁺ regulatory T cells. *AAI (American Association of Immunologists) 2010 Annual Meeting*. Baltimore, MD. May 7~11, 2010.
118. TNF-TNFR2 interaction activates regulatory T cells. Amegen Corporation, Seattle. May 14, 2009.
119. TNFR2⁺ T regulatory cells: a promising cellular target in tumor immunotherapy. *Keystone Symposia: Mobilizing Cellular Immunity for Cancer Therapy*. Snowbird, Utah. January 11 - 16, 2009.
120. Regulation of T regulatory cells. Pennington Biomedical Research Center. Baton Rouge, LA. November 8, 2008.
121. Pharmacological manipulation of activity of T regulatory cells: implication for anti-tumor TCM study. *The 2nd International Congress of TCM and Integrated TCM-*

WM Oncology and The 11th National Academic Congress of Integrated TCM-WM Oncology. Grand View Garden Hotel. Beijing, China. October 24-26, 2008.

122. Tracking CD4 T regulatory cells in autoimmune disease and cancer. *Immunotherapy vs. Immunosuppression Symposium*. Natcher Conference Center. NIH, Bethesda, Maryland. Oct 15, 2008.
123. Co-expression of TNFR2 and CD25 identifies functional CD4+FoxP3+ T regulatory cells in human peripheral blood. *2008 NIH Immunology Retreat*. Wyndham Gettysburg Hotel, Gettysburg, PA. October 1~3, 2008.
124. Expression of TNFR2 defines a unique subset of mouse CD4+CD25+ T regulatory cells with maximal suppressive functions: applicability to tumor infiltrating T regulatory cells. *Keystone Symposium: Inflammation, Microenvironment and Cancer*. Snowbird, Utah. March 30-April 4. 2008.
125. Targeting Check Points of Immune Response by Traditional Chinese Medicines: A Trans-cultural Study. *Cancer Researchers & CAM Practitioners: Fostering Collaborations; Advancing the Science*. NIH, Bethesda, Maryland. October 22-23, 2007.
126. Expression of TNFR2 defines a unique subset of CD4+CD25+ T regulatory cells with more potent suppressive capacity. *2007 NIH Immunology Retreat*. Airlie Conference Center in Warrenton, Virginia. Oct. 1-3, 2007.
127. Therapeutic Potential of Targeting Chemokines and Chemokine Receptors with Traditional Chinese Medicines. *2007 International BioEco*. Tianjin, China. June 25-28, 2007.
128. Interaction of TNF with TNF Receptor 2 Promotes the Expansion and Function of Mouse CD4⁺CD25⁺ T Regulatory Cells. *Keystone Symposia: Regulatory T Cells (B3)*. Fairmont Hotel Vancouver, Vancouver, British Columbia, Canada. Feb 1 - 6, 2007.
129. Pertussis toxin (PTx) by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. *Cytokine Interest Group Minisymposium: IL-17 and IL-23 in autoimmunity, infection and inflammation*. Lipsett Auditorium, Blg 10, NIH, Bethesda, MD. Jan 18, 2007.
130. Therapeutic Potential of Targeting Chemokines and Chemokine Receptors with Traditional Chinese Medicines. *Establishment Conference of Specialty Committee of Tumor of World Federation of Chinese Medicine Societies*. Shenyang, China. August 4-Aug 6, 2006.
131. Ying and Yang Immune Effects of Tumor Necrosis Factor-alpha is based on Effects on CD4+CD25+ T Regulatory Cells and T Effector Cells. *American Association of Immunologists (AAI) 2006 Annual Meeting*. Hynes Convention Center, Boston, Massachusetts. May 12-16, 2006.

132. Targeting Chemokines and Chemokine Receptors with Traditional Chinese Medicine has Therapeutic Anti-tumor Potential. *2nd NY Chinese Medicine Forum: Traditional Chinese Medicine & Oncology Conference*. Sheraton Hotel, Flushing, New York. April 16, 2006
133. Targeting Chemokines and Chemokine Receptors with Traditional Chinese Medicine has Therapeutic Anti-tumor Potential. *Chinese Medicine and Cancer Research: Fostering Collaborations, Advancing the Science*. Lister Hill Auditorium. NIH. Bethesda, MD. April 10-12, 2006.
134. Therapeutic Potential of Targeting Chemokines and Chemokine Receptors with Traditional Chinese Medicines. *The 1st International forum on development of traditional Chinese medicine*. Chinese Academy of Traditional Chinese Medicine. Nov 18-20, 2005
135. Pertussis Toxin as an Adjuvant Suppresses the Number and Function of CD4+CD25+ T regulatory Cells. *2005 NIH Immunology Retreat*. Airlie Conference Center in Warrenton, Virginia. Sept 19-21, 2005.
136. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic cell maturation and migration. *Keystone Symposium: Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology*. Vancouver, Canada. Feb 1-7, 2005.
137. Combination of Dexamethasone and IL-2 Expands Functional Foxp3+CD4+CD25+ T regulatory cells in vivo and Suppresses Experimental Autoimmune Encephalomyelitis (EAE). *2004 NIH Immunology Retreat*. Airlie Conference Center in Warrenton, Virginia. October 13-15, 2004.
138. Inhibitory effects of traditional Chinese medicinal components. *Symposium on the Advancement of Rheumatoid Arthritis*. Baptist University of Hong Kong. Hong Kong, China. 2004, September 27.
139. Yin Zi Huang, an injectable multi-component Chinese herbal medicine, is a potent inhibitor of T cell activation. *2004 Annual Meeting: American Association of Immunologists/ Experimental Biology (EB) 2004*. April 17-21. Washington DC.
140. Stimulatory effect of Tetrandrine (TET), a molecularly defined immunosuppressive component of Chinese herbal medicine, on CD4+CD25+ T regulatory cells. *Keystone Symposium: Regulatory/Suppressor T Cells (D1)*. Banff Center, Alberta, Canada. March 10-15. 2004.
141. Tannic Acid Is A Novel SDF-1 α /CXCR4 Inhibitor with Potential Anti-angiogenic Activity. *18th Annual Meeting of International Society for Biological Therapy of Cancer (iSBT)*. Hyatt Regency, Bethesda, MD. Oct. 30-Nov.2, 2003.

142. Identification of polyphenolic compounds in Chinese Herbal Medicine As A Novel SDF-1 α /CXCR4 Inhibitors With Potential Anti-tumor effects. *19 Annual Meeting on Oncogenes*, Hood College, Frederick, MD. June 18-21, 2003.
143. Differences in CD4+CD25+ T regulatory cell suppression of CD4+CD25- T responder cell between BALB/c and C57 BL/6 Mice. *2003 NIH Immunology Retreat*. Airlie Conference Center in Warrenton, Virginia. October 28-30, 2003.
144. Differential Response of Murine CD4+CD25+ and CD4+CD25- T Cells to Dexamethasone-induced Cell Death. *Keystone Symposium: Mechanisms of Immunologic Tolerance and its Breakdown*. Snowbird, Utah. Jan 7-12. 2003.
145. Differential Apoptotic Response of CD4+CD25- and CD4+CD25+ T Cell to Dexamethasone: A Crucial Role of IL-2. *2002 NIH Immunology Retreat*. Airlie Conference Center in Warrenton, Virginia. Oct 28-30, 2002.
146. Chemokine and its receptor: a new domain in pharmacological research of TCM. *The 2nd World Congress of Integrated Medicine*. International Convention Center, Beijing, China. Sept. 21~24, 2002.
147. Tannic Acid Is A Novel SDF-1 α /CXCR4 Inhibitor with Anti-angiogenic Activity. *American Association of Cancer Research 93rd Annual Meeting*. Moscone Convention Center, San Francisco, CA. April 6~10, 2002.
148. Identification of Tannic Acid as a novel SDF-1 α /CXCR4 Antagonist. *Comprehensive Cancer Care Conference 2001: Integrating Complementary and Alternative Therapies*. Hyatt Regency Crystal City, Arlington, VA, USA. October 17-21, 2001.
149. Shikonin, a small molecule compound from Chinese herbal medicine with anti-inflammatory and anti-HIV-1 property, is an inhibitor of multiple chemokine receptors. *16th Annual Meeting - Society for Biological Therapy*. Natcher Auditorium, National Institute of Health, Bethesda, Maryland, USA. November 8-11, 2001
150. Identification of chemoattractant receptor antagonists in natural products with potential anti-inflammatory and anti-angiogenic activities. *Gordon Research Conference: Chemotherapy of Experimental and Clinical Cancer*. Colby-Sawyer College, New London, NH, USA. July 15 - 19, 2001
151. Regulatory effects of Deoxycholic acid (DCA), one component of anti-inflammatory traditional Chinese drug-Niu Huang, on human leukocyte response to chemoattractants. *Experimental Biology 2001*. Orlando, Florida. March 31-April 4, 2001.
152. Deoxycholic acid and shikonin are the novel chemoattractant/chemokine receptor antagonist. *National Institute of Health (NIH) Technology Transfer Forum*. Natcher Auditorium, National Institute of Health, Bethesda, Maryland, USA. March 23, 2001.

153. Shikonin, a component of lithospermum erythrorhizon, selectively inhibits RANTES and MIP-1 binding--Discovery of a non-peptide, small molecule compound from traditional Chinese medicine that selectively blocks CC Chemokine Receptor-1. *The First International Conference of Traditional Chinese Medicine: Science, Regulation and Globalization*. University of Maryland, College Park, Maryland. August 27-29, 2000.
154. Deoxycholic and chenodeoxycholic acids inhibit monocyte function by blocking fMLP receptor. *Society of Leukocyte Biology Annual Meeting*. Hilton Head, South Carolina, 5-9 December 1999.
155. Regulative Effects of Jiawei-Yupingfeng-Tan (Modified Jewel Screen Powder, MJSP) and Astragalus Polysaccharide (APS) on the Stress Hormones and Macrophage of Stressed Animal. *First World Integrated Medicine Congress*. Beijing, China. 26-29 October 1997.

Ad hoc referee for professional journals:

1. Acta Pharmacologica Sinica
2. American Journal of Pathology
3. American Journal of Pathology
4. American Journal of Respiratory and Critical Care Medicine
5. Arthritis & Rheumatism
6. Arthritis Research and Therapy
7. Biomarker Insights
8. Blood
9. BMC Cancer
10. BMC Immunology
11. Cancer Biology & Medicine
12. Cancer Immunology, Immunotherapy
13. Cancer Letters
14. Cancer Research
15. Cell Reports
16. Cellular & Molecular Immunology
17. Chemotherapy
18. Chinese Medicine
19. Clinical and experimental immunology
20. Clinical Cancer Research
21. Clinical Immunology
22. Cytokine
23. European Journal of Immunology
24. European Journal of Pharmacology
25. Experimental Biology and Medicine
26. FEBS Letters
27. Frontiers in Immunology
28. Frontiers in Cell and Developmental Biology
29. Frontiers in Pharmacology
30. Haematologica/The Hematology Journal
31. Human Immunology
32. Immunology
33. International Archives of Allergy and Immunology
34. International Immunopharmacology
35. International Journal of Cancer
36. International Journal of Biological Sciences
37. International Journal of Clinical Practice
38. Journal of Alternative and Complementary Medicine
39. Journal of Biological Chemistry
40. Journal of Cancer
41. Journal of Clinical Immunology
42. Journal of Clinical Investigation
43. Journal of Control Release
44. Journal of Experimental & Clinical Cancer Research

45. Journal of Immunoassay and Immunochemistry
46. Journal of Immunology
47. Journal of Interferon & Cytokine Research
48. Journal of leukocyte biology
49. Journal of Molecular Medicine
50. Laboratory Investigation
51. MedComm
52. Molecular Cancer
53. Molecular Cancer Therapeutics
54. Nature Communication
55. Nature Clinical Practice Rheumatology
56. Nature Reviews in Rheumatology
57. Nature Medicine
58. Oncology Reports
59. Oncotarget
60. OncoTargets and Therapy
61. PeerJ
62. Pharmacological Research
63. Phytomedicine
64. Phytotherapy Research
65. PLOS One
66. PNAS
67. Scandinavian Journal of Immunology
68. Science Advances
69. Science Signaling
70. Scientific Reports
71. Theronostic

Grand reviewer

1. Member, International Expert Panel, National Medical Research Council, Ministry of Health, Singapore (2014-2023)
2. Member, National Medical Research Council's Clinician Scientist-Individual Research Grant (CS-IRG) Review Panel, Ministry of Health of Singapore government (2021-2023)
3. Reviewer, Health and Medical Research Fund (HMRF), The Government of the Hong Kong Special Administrative Region (HKSAR) (2013-).

Ad Hoc Grant reviewer

1. Arthritis Research UK
2. Experimental and Translational Medicine Research Committee, Scottish Government
3. Fondation pour la Recherche Médicale (France)
4. Israel Science Foundation (ISF)
5. Kidney Research UK
6. National Natural Science Foundation of China
7. Research Agency (ANR), France
8. Research Grant Council, Hong Kong SAR
9. The *Medical Research Council* (the *MRC*), UK
10. Welltrust, UK